Capitalizing leadership acumen
for life science innovations

WESTON, Fla.Dec. 3, 2018 /PRNewswire/ -- Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, is pleased to announce that it has secured $10 Million in financing from Korean company, Incon, in exchange for equity ownership. Funding will be used to advance clinical and non-clinical development of VAR 200 (2HPβCD), including production of clinical supplies, execution of the Phase 2a trial in patients with FSGS, and support for expanded access and subcutaneous delivery initiatives. The funding will also be used to expand company resources and hire select additional headcount.

-> READ MORE